Scientists have laid out an approach to block a protein that the novel coronavirus uses to cut and disable crucial components of the immune system and to produce copies of itself, an advance that may lead to new drugs against COVID-19.
The researchers, including those from the University of Texas Health Science Center at San Antonio (UT Health San Antonio) in the US, developed two molecules that inhibit the molecular "scissor" enzyme used by the coronavirus called SARS-CoV-2-PLpro.
According to the study, published in the journal Science, SARS-CoV-2-PLpro promotes infection by sensing and processing both viral and human proteins.
"This enzyme executes a double-whammy," said study senior author Shaun K. Olsen, associate professor of biochemistry and structural biology at UT Health San Antonio.
"It stimulates the release of proteins that are essential for the virus to replicate, and it also inhibits molecules called cytokines and chemokines that signal the immune system to attack the infection," Olsen said.
SARS-CoV-2-PLpro cuts human proteins ubiquitin and ISG15, which help maintain protein integrity by acting like a molecular scissor, he explained.
The scientists developed the inhibitors, which are very efficient at blocking the activity of SARS-CoV-2-PLpro, yet do not recognise other similar proteins in human cells.
"This is a critical point: The inhibitor is specific for this one viral enzyme and doesn't cross-react with human enzymes with a similar function," he added.
The researchers said this specificity would be a key determinant of the therapeutic value of the approach.
When the scientists compared SARS-CoV-2-PLpro against similar enzymes from coronaviruses of recent decades such as the 2002-03 SARS pandemic virus, they learned that it processes ubiquitin and ISG15 much differently than its counterpart.
"One of the key questions is whether that accounts for some of the differences we see in how those viruses affect humans, if at all," Olsen said.
By understanding similarities and differences of these enzymes in various coronaviruses, the researchers said it may be possible to develop inhibitors that are effective against multiple viruses.
Olsen said these inhibitors could also be potentially modified when other coronavirus variants emerge in the future.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU